Overview
Advancing DMT for Stroke
Algernon NeuroScience (AGN Neuro) is a wholly owned private subsidiary of Grey Matters Health Inc. and has been established to advance its DMT program for stroke and traumatic brain injury (TBI).
There are more than 12.2 million new strokes each year globally, with 7.6 million (62%) of these being ischemic, meaning a clot blocks blood flow to the brain. The balance are hemorrhagic strokes where there is bleeding in the brain. There are 6.5 million people who die from stroke annually, with one in four people over the age of 25 expected to have a stroke in their lifetime. Over 63 million years of healthy life is lost each year due to ischemic stroke-related death and disability. 1
Source 1: The World Stroke Organization (WSO)
Advancing DMT for Traumatic Brain Injury (TBI)
According to the National Institute of Neurological Disorders and Stroke, a TBI can be caused by a forceful bump, blow, or jolt to the head or body, or from an object that pierces the skull and enters the brain. Not all blows or jolts to the head result in a TBI. Some types of TBI can cause temporary or short-term problems with normal brain function, including problems with how the person thinks, understands, moves, communicates, and acts. More serious TBI can lead to severe and permanent disability, and even death.2 There are an estimated 69 million people globally that experience TBI every year.3
Source 2: National Institute of Neurological Disorders and Stroke
Source 3: National Library of Medicine
About Grey Matters Health Inc.
Grey Matters Health Inc. is a Canadian healthcare company, the parent of Algernon NeuroScience, and is additionally establishing of a new network of dedicated brain PET scanning clinics in the U.S. under the NovaScan Neuroimaging Clinics™ brand, for the early-stage detection of AD and other forms of dementia, as well as epilepsy, neuro-oncology, and movement disorders including Parkinson’s disease.
For further information about Grey Matters Health Inc. please visit www.greymatters-health.com
Feature Video
Algernon NeuroScience CEO Christopher J. Moreau discusses the company’s mandate to investigate DMT for stroke and traumatic brain injury (TBI) treatment.